The use of GLP-1 receptor agonists, such as liraglutide and semaglutide, in medical treatments for obesity has gained traction. These medications mimic the effects of GLP-1, helping individuals achieve and maintain weight loss. By targeting both glucose control and appetite regulation, GLP-1-based therapies offer a comprehensive approach to weight management, making them valuable tools in treating obesity and related metabolic disorders.